CHRS — Coherus Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00
- $117.51m
- $222.37m
- $257.24m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 89.8 | 132 | -287 | -292 | -238 |
Depreciation | |||||
Non-Cash Items | 49.2 | 51.1 | 203 | 126 | 96 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -114 | -32.1 | 42.9 | -79.3 | -36.8 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 28.4 | 154 | -37.4 | -241 | -175 |
Capital Expenditures | -1.82 | -7.23 | -1.29 | -2.04 | -0.286 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -10.9 | -7.17 | -137 | -165 | 145 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -12.7 | -14.4 | -138 | -167 | 145 |
Financing Cash Flow Items | -0.815 | -0.88 | -1.75 | -4.97 | -4.62 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 89.4 | 224 | 51.9 | 54.3 | 69.6 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 105 | 364 | -124 | -354 | 39.4 |